当K药与司美格鲁肽在“药王之争”中杀得难解难分时,曾霸榜全球药王11年的艾伯维,正以一场堪称“教科书”式的战略转型,悄然完成从“修美乐依赖”到“多引擎驱动”的蜕变。财报背后的“教科书式破局”4月25日披露的2025年艾伯维Q1财报显示:⦁ 公司净收入133.43亿美元,同比增长8.4%,超预期4.4亿美元;⦁ 免疫、神经科学、肿瘤、美学四大板块全面开花,收入分别达62.64亿、22.82亿、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.